The pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 provoked the rapid generation and mass production of vaccines against the virus. In this serious situation, the European Medicines Agency (EMA) quickly authorized several COVID-19 vaccines: the tozinameran mRNA vaccine (produced by Pfizer-Biontech Laboratory), the CX-024414 mRNA (by Moderna), the chimpanzee adenoviral vector CHADOX1 NCOV-19 (by AstraZeneca), and the adenoviral vector type 26 AD26.COV2.S (by Janssen). Although no major adverse events about the vaccines were found during pivotal clinical trials, previously unpublished adverse drug reactions (ADRs) were reported post-marketing.
